Amylyx Pharmaceuticals Completes Randomization of Last Participant in Phase 3 Avexitide Trial
Amylyx Pharmaceuticals announced that the last participant has been randomized and dosed in the Phase 3 Lucidity clinical trial of avexitide. Lucidity is a 16-week, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gastric bypass surgery. Participants who complete the 16-week double-blind period are eligible to enter a 32-week open-label extension period. The trial has enrolled 78 participants, with topline data readout anticipated in Q3 2026. If approved, commercial launch of avexitide is anticipated in 2027.
